Search Results for: FGFR1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
KPNB1 karyopherin subunit beta 1
  • ISG15 antiviral mechanism
  • Apoptosis induced DNA fragmentation
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Transport of Ribonucleoproteins into the Host Nucleus
  • NS1 Mediated Effects on Host Pathways
  • Nuclear import of Rev protein
  • Nuclear import of Rev protein
  • Initiation of Nuclear Envelope (NE) Reformation
  • Neutrophil degranulation
  • Postmitotic nuclear pore complex (NPC) reformation
  • Inhibition of nitric oxide production
L1CAM L1 cell adhesion molecule
  • Basigin interactions
  • L1CAM interactions
  • L1CAM interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Signal transduction by L1
  • Ethanol
  • Hereditary spastic paraplegia (SPG)
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • L1 syndrome, including: ; X-linked hydrocephalus; MASA syndrome; X-linked complicated spastic paraplegia type I ; X-linked partial agenesis of corpus callosum
LDHA lactate dehydrogenase A
  • Pyruvate metabolism
  • NADH
  • Etheno-NAD
  • Nicotinamide
  • Oxamic Acid
  • Stiripentol
  • Copper
  • Artenimol
MFHAS1 malignant fibrous histiocytoma amplified sequence 1
MMP2 matrix metallopeptidase 2
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Extra-nuclear estrogen signaling
  • Marimastat
  • Captopril
  • SC-74020
  • Halofuginone
  • AE-941
  • Endostatin
  • Choriocarcinoma
  • Penile cancer
  • Torg-Winchester syndrome
NCAM1 neural cell adhesion molecule 1
  • ECM proteoglycans
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • NCAM1 interactions
  • NCAM1 interactions
  • Signal transduction by L1
  • RAF/MAP kinase cascade
  • Interferon gamma signaling
NCK1 NCK adaptor protein 1
  • Downstream signal transduction
  • Generation of second messenger molecules
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Nephrin family interactions
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
NCK2 NCK adaptor protein 2
  • Downstream signal transduction
  • Nephrin family interactions
  • Ephrin signaling
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • Regulation of cortical dendrite branching
NECTIN1 nectin cell adhesion molecule 1
  • Adherens junctions interactions
  • Nectin/Necl trans heterodimerization
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
NEDD4 NEDD4 E3 ubiquitin protein ligase
  • ISG15 antiviral mechanism
  • Downregulation of ERBB4 signaling
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Antigen processing: Ubiquitination & Proteasome degradation
NRP1 neuropilin 1
  • Neurophilin interactions with VEGF and VEGFR
  • Signaling by ROBO receptors
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Signal transduction by L1
  • CHL1 interactions
PDGFRB platelet derived growth factor receptor beta
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Becaplermin
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • XL999
  • XL820
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Nintedanib
  • Polaprezinc
  • Trapidil
  • Foreskin fibroblast (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Ripretinib
  • Pralsetinib
  • Glioma
PDK1 pyruvate dehydrogenase kinase 1
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Signaling by Retinoic Acid
  • 4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE
  • Dichloroacetic acid
PDP1 pyruvate dehydrogenase phosphatase catalytic subunit 1
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Pyruvate dehydrogenase complex deficiency; X-linked Leigh syndrome
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Isoprenaline
  • SF1126
  • Enzastaurin
  • Wortmannin
PIK3R2 phosphoinositide-3-kinase regulatory subunit 2
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • Downstream signal transduction
  • Rho GTPase cycle
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Isoprenaline
  • SF1126
PKM pyruvate kinase M1/2
  • Neutrophil degranulation
  • Pyruvic acid
  • L-Phospholactate
  • 2-Phosphoglycolic Acid
  • 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
  • 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine
  • 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
  • Copper
  • Artenimol
PLCG1 phospholipase C gamma 1
  • ISG15 antiviral mechanism
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • PLC-gamma1 signalling
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream signal transduction
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • Role of phospholipids in phagocytosis
  • PECAM1 interactions
  • EGFR interacts with phospholipase C-gamma
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Role of second messengers in netrin-1 signaling
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated cell proliferation
  • Constitutive Signaling by EGFRvIII
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PLCG1
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through PLCG1
  • FCGR3A-mediated IL10 synthesis
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
PTK6 protein tyrosine kinase 6
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin D associated events in G1
  • ERBB2 Activates PTK6 Signaling
  • PTK6 Regulates Proteins Involved in RNA Processing
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • PTK6 Regulates Cell Cycle
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • PTK6 Down-Regulation
  • PTK6 Expression
  • PTK6 Activates STAT3
  • PTK6 promotes HIF1A stabilization
  • Vandetanib
  • Fostamatinib
  • Zanubrutinib
PTPN1 protein tyrosine phosphatase non-receptor type 1
  • Integrin signaling
  • Negative regulation of MET activity
  • Regulation of IFNG signaling
  • PTK6 Down-Regulation
  • MECP2 regulates neuronal receptors and channels
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
  • 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid
  • 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
  • [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
  • {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
  • Compound 19
  • 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
  • 2-(Oxalyl-Amino)-Benzoic Acid
  • {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
  • Novo Nordisk a/S Compound
  • N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide
  • 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • PNU177836
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
  • (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
  • 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
  • L-cysteic acid
  • 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
  • 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid
  • Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
  • 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
  • 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
  • [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
  • {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
  • N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide
  • 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
  • ISIS 113715
  • Trodusquemine
  • Ertiprotafib
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
  • [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
  • 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
  • [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
  • 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
  • 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
  • 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
  • 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
  • N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
  • [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
  • 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
  • ISOTHIAZOLIDINONE ANALOG
  • 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
  • p-Benzoyl-L-phenylalanine
  • 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
  • (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
  • 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
  • (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid

Page 3 out of 4 pages